The grey matter in the brain may hold vital clues for early, accurate detection in Alzheimer’s, and potentially also help pharma to find new drug treatments.
The third webinar* in the COVID-19 monthly briefing series was designed to provide insight from life sciences thought-leaders and to generate discussion on issues that pharma and biotech co
Being diagnosed with a rare disease is often a bolt from the blue, and while each person’s journey is different, there are common challenges that bind patient communities together.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
